Generic Name and Formulations:
Ceritinib 150mg; hard gel caps.
Novartis Pharmaceuticals Corp
Indications for ZYKADIA:
Treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.
Take with food. 450mg once daily until disease progression or unacceptable toxicity. Discontinue if 150mg once daily with food not tolerated. Severe hepatic impairment or if concomitant use of strong CYP3A4 inhibitors unavoidable: reduce ceritinib dose by ⅓. Dose modifications: see full labeling.
Monitor for severe or persistent GI toxicity; if occurs, withhold until improved; resume at reduced dose. Monitor ALT/AST and total bilirubin once monthly, and more frequently if elevated transaminases develop; withhold then reduce dose, or permanently discontinue if ALT/AST elevation >3xULN with total bilirubin >2xULN in the absence of cholestasis or hemolysis. Congenital long QT syndrome; avoid. Patients with CHF, bradyarrhythmias, electrolyte abnormalities, or those who are taking drugs known to prolong the QTc interval; monitor ECG, electrolytes periodically. Permanently discontinue if QTc prolongation in combination with Torsade de pointes or polymorphic ventricular tachycardia or serious arrhythmia develop. Monitor HR and BP regularly; fasting serum glucose, lipase, amylase prior to initiation and periodically thereafter. Monitor for pulmonary symptoms as clinically indicated. Permanently discontinue if treatment-related interstitial lung disease (ILD)/pneumonitis, uncontrolled hyperglycemia, or life-threatening bradycardia occur. Severe hepatic impairment. Embryo-fetal toxicity. Pregnancy. Use effective contraception during treatment and for 6 months (females) or 3 months (males) after completion. Nursing mothers: not recommended (during and for 2 weeks after completion).
Tyrosine kinase inhibitor.
See Adults. Potentiated by strong CYP3A4 inhibitors (eg, ritonavir, macrolides, ketoconazole, nefazodone), grapefruit juice; avoid. Avoid concomitant strong CYP3A4 inducers (eg, carbamazepine, phenytoin, rifampin, St. John’s Wort). Avoid concomitant CYP3A substrates (eg, alfentanil, cyclosporine, ergots, fentanyl, pimozide, quinidine, sirolimus, tacrolimus) or CYP2C9 substrates with narrow therapeutic indices (eg, phenytoin, warfarin); if unavoidable, reduce doses of these drugs. Avoid concomitant agents known to cause bradycardia (eg, beta-blockers, non-dihydropyridine CCBs, clonidine, digoxin).
Diarrhea, nausea, fatigue, vomiting, abdominal pain, decreased appetite, weight loss; hepatotoxicity, ILD/pneumonitis, QT prolongation, hyperglycemia, bradycardia, pancreatitis.
Endocrinology Advisor Articles
- Diet Quality and Glycemic Control in Women With Gestational Diabetes
- Most Foods Containing Fructose Do Not Have Harmful Effect on Glycemic Control
- Effects of a Low-Carbohydrate Diet on Weight Loss Maintenance
- Sleep Quality in Women With Surgical vs Natural Menopause
- Unhealthy Lifestyle and Rotating Night Shifts Put Nurses at Higher Risk for T2D
- Hypothyroidism Treatment No Longer Available
- Obesity Subtype May Determine Outcomes After Bariatric Surgery
- Few Physicians Work in Practices That Use Telemedicine
- Skin Autofluorescence Predicts T2D, Heart Disease, Mortality
- ACC: Smoking Cessation Expert Decision Pathway Emphasizes Team-Based Support